Localized osteosarcoma

Summary

Localized osteosarcoma (MONDO:0002620) is a disease and 8 clinical trials. Top therapeutic interventions include cabozantinib, ifosfamide, and peginterferon alfa-2b. A subtype of osteosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	localized osteosarcoma
Mondo ID	MONDO:0002620
DOID	DOID:3356
NCIT	C7780
UMLS	C0278511
MedGen	124467
Is cancer (heuristic)	no

Also known as: localized osteogenic sarcoma · localized osteosarcoma · osteosarcoma, localised · osteosarcoma, localized

Disease family

This is a subtype of osteosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › osteosarcoma › localized osteosarcoma

Related subtypes (5): extraosseous osteosarcoma, multifocal osteogenic sarcoma, pediatric osteosarcoma, bone osteosarcoma, low grade central osteosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	6
PHASE3	1
PHASE2/PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05691478	PHASE2/PHASE3	RECRUITING	A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
NCT00134030	PHASE3	COMPLETED	Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma
NCT04890067	Not specified	RECRUITING	Observational Study in Localized Osteosarcoma
NCT00954473	Not specified	COMPLETED	Study of Blood Samples From Patients With Osteosarcoma
NCT01190943	Not specified	COMPLETED	DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma
NCT01374672	Not specified	COMPLETED	Biomarkers in Predicting Response to Chemotherapy in Samples From Young Patients With Osteosarcoma
NCT01807052	Not specified	COMPLETED	Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas
NCT03737435	Not specified	COMPLETED	Tumor Microenvironment in Patients With Localized Osteosarcoma Treated With Mifamurtide: a Translational Study

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	3
IFOSFAMIDE	4	1
PEGINTERFERON ALFA-2B	4	1